PBAC backs historic funding model

In a major breakthrough in the way medicines are funded in Australia, the PBAC has recommended a broad listing for BMS' immunotherapy drugs Opdivo and Yervoy in advanced or metastatic cancers.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here